Nektar Therapeutics Stock (NASDAQ:NKTR)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$0.93

52W Range

$0.48 - $1.93

50D Avg

$1.19

200D Avg

$1.26

Market Cap

$166.10M

Avg Vol (3M)

$1.76M

Beta

0.61

Div Yield

-

NKTR Company Profile


Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

137

IPO Date

May 03, 1994

Website

NKTR Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22Dec 21
Product$20.68M$20.35M$23.73M
License Collaboration And Other Revenue$520.00K$1.91M$436.00K
Non Cash Royalty Revenue Related To Sale Of Future Royalties$68.92M$69.79M$77.75M
Royalty---

Fiscal year ends in Dec 23 | Currency in USD

NKTR Financial Summary


Dec 23Dec 22Dec 21
Revenue$90.12M$92.06M$101.91M
Operating Income$-263.68M$-240.24M$-446.10M
Net Income$-276.06M$-368.20M$-523.84M
EBITDA$-263.68M$-220.54M$-453.80M
Basic EPS$-1.45$-1.97$-2.86
Diluted EPS$-1.45$-1.97$-2.86

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 24Nov 08, 24 | 12:21 AM
Q1 24May 09, 24 | 12:00 AM
Q4 23Mar 04, 24 | 10:54 PM

Peer Comparison


TickerCompany
SPROSpero Therapeutics, Inc.
NUVBNuvation Bio Inc.
ACHLAchilles Therapeutics plc
NXTCNextCure, Inc.
CTMXCytomX Therapeutics, Inc.
ASMBAssembly Biosciences, Inc.
TILInstil Bio, Inc.